Skip to main content
Erschienen in: Rheumatology International 2/2013

01.02.2013 | Original Article

Prevalence and significance of the MEFV gene mutations in childhood Henoch–Schönlein purpura without FMF symptoms

verfasst von: Cagla Serpil Dogan, Sema Akman, Mustafa Koyun, Turker Bilgen, Elif Comak, Arife Uslu Gokceoglu

Erschienen in: Rheumatology International | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Familial Mediterranean fever (FMF) has been reported more frequently in patients presenting with Henoch–Schönlein purpura (HSP) than in the general population. But, there is no clear knowledge about MEFV mutations in patients with HSP. We investigated the prevalence of MEFV mutations in children with HSP and without FMF whether these mutations have any effect on the disease course or complications. A total of 76 children with HSP who had no typical symptoms of FMF were screened for the mutations in exon 2 and exon 10 of the MEFV gene. Eleven of 76 patients (14.4 %) were heterozygous (E148Q in 5, M694V in 4, M680I in 1, E148V in 1), 5 (6.6 %) were homozygous (M694V/M694V in 4, V726A/V726A in 1), and 2 (2.6 %) were compound heterozygous (E148Q/M694V mutations in 1 and L110P/E148Q mutations in 1). Altogether, 7 patients carried 2 mutated MEFV alleles (9.2 %), which was higher than that observed in the general Turkish population (1 %). No significant differences in joint, gastrointestinal, renal involvement, or subcutaneous edema, and also acute phase reactants including leukocyte count, erythrocyte sedimentation rate, and serum C-reactive protein concentration were found between the groups. The prevalence of the two allele-MEFV mutations in patients with HSP was found higher than that of the general population. However, it seems that MEFV gene mutations may not have any effect on the clinical presentation of HSP.
Literatur
1.
Zurück zum Zitat Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRef Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRef
2.
Zurück zum Zitat Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9:473–483PubMedCrossRef Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9:473–483PubMedCrossRef
3.
Zurück zum Zitat Mimouni A, Magal N, Stoffman N et al (2000) Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 105(5):E70PubMedCrossRef Mimouni A, Magal N, Stoffman N et al (2000) Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 105(5):E70PubMedCrossRef
4.
Zurück zum Zitat Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146–149PubMedCrossRef Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146–149PubMedCrossRef
5.
Zurück zum Zitat Kutlay S, Yilmaz E, Koytak ES, Tulunay OO, Keven K, Ozcan M, Ertürk S (2001) Case of familial Mediterranean fever with amyloidosis as the first manifestation. Am J Kidney Dis 38(6):E34PubMedCrossRef Kutlay S, Yilmaz E, Koytak ES, Tulunay OO, Keven K, Ozcan M, Ertürk S (2001) Case of familial Mediterranean fever with amyloidosis as the first manifestation. Am J Kidney Dis 38(6):E34PubMedCrossRef
6.
Zurück zum Zitat Ozdogan H, Arisoy N, Kasapçapur O et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327PubMed Ozdogan H, Arisoy N, Kasapçapur O et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327PubMed
7.
Zurück zum Zitat Tekin M, Yalçinkaya F, Tümer N, Akar N, Misirlioğlu M, Cakar N (2000) Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. Acta Paediatr 89:177–182PubMedCrossRef Tekin M, Yalçinkaya F, Tümer N, Akar N, Misirlioğlu M, Cakar N (2000) Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. Acta Paediatr 89:177–182PubMedCrossRef
8.
Zurück zum Zitat Touitou I, Magne X, Molinari N et al (2000) MEFV mutations in Behçet’s disease. Hum Mutat 16:271–272PubMedCrossRef Touitou I, Magne X, Molinari N et al (2000) MEFV mutations in Behçet’s disease. Hum Mutat 16:271–272PubMedCrossRef
9.
Zurück zum Zitat Saulsbury FT (2007) Clinical update: Henoch-Schönlein purpura. Lancet 24:976–978CrossRef Saulsbury FT (2007) Clinical update: Henoch-Schönlein purpura. Lancet 24:976–978CrossRef
10.
Zurück zum Zitat Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806PubMedCrossRef Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806PubMedCrossRef
11.
Zurück zum Zitat Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 143:658–661PubMedCrossRef Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 143:658–661PubMedCrossRef
12.
Zurück zum Zitat Ozçakar ZB, Yalçinkaya F, Cakar N et al (2008) MEFV mutations modify the clinical presentation of Henoch-Schönlein purpura. J Rheumatol 35:2427–2429PubMedCrossRef Ozçakar ZB, Yalçinkaya F, Cakar N et al (2008) MEFV mutations modify the clinical presentation of Henoch-Schönlein purpura. J Rheumatol 35:2427–2429PubMedCrossRef
13.
Zurück zum Zitat Bayram C, Demircin G, Erdoğan O, Bülbül M, Catlık A, Akyüz SG (2011) Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura. Acta Paediatr 100:745–749PubMedCrossRef Bayram C, Demircin G, Erdoğan O, Bülbül M, Catlık A, Akyüz SG (2011) Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura. Acta Paediatr 100:745–749PubMedCrossRef
14.
Zurück zum Zitat Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRef Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRef
15.
Zurück zum Zitat Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schönlein nephritis. Pediatr Nephrol 22:64–70PubMedCrossRef Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schönlein nephritis. Pediatr Nephrol 22:64–70PubMedCrossRef
16.
Zurück zum Zitat Xia Y, Mao J, Chen Y et al (2011) Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26:1083–1088PubMedCrossRef Xia Y, Mao J, Chen Y et al (2011) Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26:1083–1088PubMedCrossRef
17.
Zurück zum Zitat Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRef Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRef
18.
Zurück zum Zitat Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920PubMedCrossRef Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920PubMedCrossRef
Metadaten
Titel
Prevalence and significance of the MEFV gene mutations in childhood Henoch–Schönlein purpura without FMF symptoms
verfasst von
Cagla Serpil Dogan
Sema Akman
Mustafa Koyun
Turker Bilgen
Elif Comak
Arife Uslu Gokceoglu
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 2/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2400-x

Weitere Artikel der Ausgabe 2/2013

Rheumatology International 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.